Reports

Amgen and Entera Collaborate on Serious Illness Treatment Program

Amgen and Entera Bio are partnering up to develop new treatments for inflammatory disease and certain other serious illnesses using the Entera drug discovery program. The platform will be used to develop oral formulations for one preclinical large molecule program which Amgen has selected. Entera’s CEO said the collaboration would be an important validation test of the platform technology.

CRISPR Babies Could Face Unintended Consequences of Editing

The CCR5 gene has been researched by scientists since the 1990s, and has a number of roles which have not yet properly been uncovered. Loss of the gene’s function is known, however, to increase the risk of potentially fatal reactions to some diseases, and has shown an ability to enhance learning in mice.

Genetic Heart Test Used to Identify Risk of Severe Cardiomyopathy

Scientists from the University of Pennsylvania have created a test using gene-editing tools such as CRISPR to identify a gene variant responsible for severe hypertrophic cardiomyopathy (SHC). SHC is an often-familial disease which thickens heart walls and is linked to a variant in the TNNT2 gene.

CEPI Provides $8.4 Million Grant to Fight “Disease X”

A new deal created by the Coalition for Epidemic Preparedness Innovations (CEPI) will use $8.4m to facilitate development of a vaccine platform to fight unknown pathogens. Under the deal, Imperial College London will work to create a self-amplifying RNA vaccine platform, which can then be made to rapidly develop anti-pathogen vaccines.

SeraCare Acquired by LGC

Manufacturer of quality control materials SeraCare Life Sciences has been acquired by LGC, an international life sciences measurement and testing company, strengthening its position in the clinical quality control tools market.

Role of PIF1 Repair Protein Explored in New Study

Researchers in Spain have specified the role that the protein PIF1, which can undo different structures in these molecules, plays in the human body. The study found that PIF1 contains the material to allow cells to function properly, and that improperly-repaired damage to the protein can cause problems for health.

UCB to Invest £1 Billion in UK R&D

Multinational biopharmaceutical company UCB has agreed to invest £1 billion in UK research and development (R&D), the government has announced in its latest Life Sciences Sector Deal. In the deal, £75 million will be invested into the development of new AI driven diagnostic tests while £50 million will be invested in digital pathology programmes and £37.5 million into regional digital innovation hubs.

Scientists Create Ten-Minute Universal Test for Cancer

A universal test which can detect traces of any cancer in a patient’s bloodstream in ten minutes has been developed by scientists from the University of Queensland. As it stands the test has a sensitivity of 90%, so is able to detect 90 in 100 cases of cancer.

New Study Details CRISPR to Molecular Level

A new study by the the Novo Nordisk Foundation Center for Protein Research details how CRISPR-Cas12a works, right down to the molecular level. This should make it possible to fine-tune the process to achieve better results.